Abstract 431P
Background
Breast cancer survivors (BCS) often experience cancer-related fatigue (CRF), a distressing condition which does not have an effective standardised pharmacological intervention. Xiang Bei Yangrong Tang (XBYRT), a modified herbal traditional Chinese medicine (TCM) decoction, is formulated for the management of CRF in BCS. In this in vitro study, we evaluated the herb-enzyme inhibition for 9 of the herbal TCMs from the XBYRT formulation, on CYP2D6 activity.
Methods
The XBYRT herbal components evaluated were Radix Astragaliseu Hedysari, Radix Codonopsis Pilosulae, Rhizoma Atractylodis Macrocephalae, Poria cocos, Radix Paeoniae Alba, Fructus Ligustri Lucidi, Rhizoma Cyperi, Radix Polygalae and Bulbus Fritillariae Thunbergii. Varying concentrations of the herbal TCMs were assayed for herb-enzyme inhibition using the Vivid P450 CYP2D6 assay kit. The percentage inhibition for the maximum XBYRT concentration and the half maximal inhibitory concentrations (IC50) were determined. The maximum XBYRT concentration was calculated based on the total dosage of herbal components consumed, without accounting for first pass metabolism. The IC50 was calculated using the non-linear regression from GraphPad Prism 5.
Results
Assayed at the maximum XBYRT concentration, herbal components exhibiting the highest inhibition levels were Radix Codonopsis Pilosulae (56.8%), Poris cocos (45.0%), Fructus Ligustri Lucidi (42.9%) and Radix Paeoniae Alba (35.5%). The IC50 values of these four herbal components were 481µg/ml, 572 µg/ml, 447 µg/ml and 475 µg/ml respectively. The other 5 herbal components exhibited <30% inhibition at the maximum XBYRT concentrations.
Conclusions
Components of XBYRT display potential CYP2D6 enzymatic inhibition activities. Hence, caution should be taken with the concomitant usage of XBYRT with drugs that are CYP2D6 substrates such as tamoxifen. In vivo and clinical studies are required to ascertain the actual effects of these herbal components on drug metabolism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Health Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract